Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Monday

Core Insights - Castle Biosciences is expected to report Q3 2025 results on November 3, 2025, with anticipated earnings of ($0.35) per share and revenue of $71.062 million [1][2] - The company previously reported Q2 2025 earnings of $0.15 per share, exceeding estimates by $0.66, with revenue of $86.18 million, surpassing expectations of $71.53 million [3] - Analysts project a $0 EPS for the current fiscal year and a $-2 EPS for the next fiscal year [3] Financial Performance - Castle Biosciences has a market capitalization of $739.76 million, with a price-to-earnings ratio of -72.86 and a beta of 1.13 [4] - The stock has fluctuated between a fifty-two week low of $14.59 and a high of $35.84, with a current stock price of $25.50 [4] - The company maintains a debt-to-equity ratio of 0.02, a quick ratio of 6.69, and a current ratio of 6.85 [4] Insider Activity - Insider Derek J. Maetzold sold 1,339 shares at an average price of $22.44, totaling $30,047.16, resulting in a 2.08% decrease in his position [5] - Following the sale, Maetzold holds 62,988 shares valued at approximately $1.41 million [5] Institutional Holdings - Institutional investors own 92.60% of Castle Biosciences, with notable increases in holdings from several firms, including a 10,592% increase from Jones Financial Companies [6] - Other significant increases include a 256.9% boost from Tower Research Capital and a 15,811.5% increase from Amundi [6] Analyst Ratings - Weiss Ratings issued a "sell (d-)" rating, while Wall Street Zen upgraded the stock from "sell" to "hold" [7] - Canaccord Genuity maintains a "buy" rating with a price target of $37.00, and Zacks Research upgraded the stock to "strong-buy" [7][8] - The consensus rating is "Moderate Buy" with an average target price of $36.57 [8] Company Overview - Castle Biosciences specializes in molecular diagnostics, providing testing solutions for dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions [9] - Key products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, and TissueCypher, which assist in risk stratification and diagnosis [9]